CRISPR Gene Editing Newsletter
Issue #58October 12, 20267 studies

A single CRISPR dose cut hereditary angioedema attack rates in a phase 3 trial

Gene editing had a busy week—from a phase 3 trial that may redefine how a rare swelling disorder is treated, to lab tools that are quietly making CRISPR sharper, faster, and harder to misuse.

Here's what moved the needle.

One Shot, Fewer Attacks: CRISPR Takes On Hereditary Angioedema 💉

  • Hereditary angioedema causes unpredictable, potentially life-threatening swelling episodes. Current long-term prophylaxis helps, but requires ongoing treatment. A phase 3 trial of lonvoguran ziclumeran—a single-dose, in vivo CRISPR-Cas9 therapy targeting the gene KLKB1—significantly reduced attack rates.
  • The catch: one dose, permanent edit, lasting effect. That's the promise. The open questions involve long-term safety, off-target edits, and what happens if something goes wrong with a change you can't undo.
  • The bigger question: as in vivo CRISPR therapies move from rare disease trials into broader medicine, the gap between what the therapy does and what we can monitor afterward is becoming harder to ignore.

Why it matters: This is one of the clearest clinical signals yet that in vivo CRISPR—editing genes inside a living person without removing cells first—can work at scale for a defined genetic disorder.

🥈 Top 2% journal 🔗 Med (New York, N.Y.) Journal Article 🗓️ Oct 9

Key Findings

Prime Editing Lambs Are Here 🐑

  • Researchers used prime editing—a CRISPR method that rewrites DNA without cutting both strands—to edit sheep embryos via electroporation, skipping the technically demanding microinjection step.
  • Of 14 live lambs born, 5 carried intended edits at targeted genes linked to tail length and reproductive traits. One short-tail lamb showed up to 51% allele frequency for the edit, with no detected off-target changes.
💡 Prime editing in large mammals just got a scalable, injection-free delivery route.
🎖️ Top 10% journal 🔗 Frontiers in genome editing Journal Article 🗓️ Oct 7

Glutathione Has a Secret Ferroptosis Exit Route 🔬

  • Ferroptosis is a form of cell death driven by lipid oxidation. It was thought that glutathione (GSH) only suppresses ferroptosis through one enzyme, GPX4. A genome-wide CRISPR screen in GPX4-knockout cells found a second pathway: GSH activates a protein called FSP1 to produce reduced ubiquinone, which independently blocks oxidized lipid buildup.
  • Blocking FSP1 eliminated this protection both in cell culture and in mice, suggesting the GSH-FSP1 axis is a real, separate mechanism—not a backup artifact.
💡 Glutathione's ferroptosis protection runs through two independent pathways, not one.
🏆 Top 0.1% journal 🔗 Cell Journal Article 🗓️ Oct 6

Botulinum Toxin's Unexpected Muscle Accomplice 💪

  • Botulinum neurotoxins are known to enter nerve cells via neuronal receptors, but how they concentrate so efficiently at neuromuscular junctions was unclear. A genome-wide CRISPR screen identified hemojuvelin (HJV), a protein abundant in skeletal muscle, as a non-neuronal receptor for two botulinum toxin types.
  • Mice lacking HJV showed markedly reduced toxin accumulation on muscle surfaces and significantly higher resistance to paralysis and lethality—suggesting HJV acts as a capture net before neuronal uptake.
💡 Muscle, not just nerve, plays an active role in botulinum toxin's entry mechanism.
🥈 Top 2% journal 🔗 Cell reports Journal Article 🗓️ Oct 6

A New CRISPR Screen Tool for Human Hepatocytes 🧫

  • Primary human liver cells don't divide in culture, making CRISPR screens in them nearly impossible—until now. Researchers developed lipofection and lentivirus delivery methods for mouse-passaged primary human hepatocytes, achieving gene editing efficiency above 90% while keeping cells viable.
  • An 85-gene screen identified host factors for hepatitis B virus infection. Knocking out the viral entry receptor in humanized mice reduced HBV infection in vivo, validating the screen's findings in a living system.
💡 Scalable CRISPR screening in human liver cells is now feasible—and it works in mice too.

A Cas12a Variant That Nicks Instead of Cuts ✂️

  • Standard CRISPR-Cas12a makes double-strand DNA breaks, which can cause chromosomal rearrangements. Researchers screened for Cas12a variants that cut only one DNA strand (nickases) and found one—called Lid2—with an entirely remodeled domain that stabilizes one strand in the active site while blocking cleavage of the other.
  • Cryo-EM at 2.5 Å resolution confirmed the structural mechanism. The nickase behavior was robust, adding a new precise-editing component to the CRISPR toolkit.
💡 A structurally novel Cas12a nickase expands options for precise, lower-risk genome editing.
🥇 Top 1% journal 🔗 Nucleic acids research Journal Article 🗓️ Oct 5

Mapping What Controls the T Cell Surface 🗺️

  • The proteins displayed on a T cell's surface define its identity, but what controls their abundance isn't just transcription. A new platform called SCITO-Perturb-seq paired genome-wide CRISPR activation with direct measurement of 201 surface proteins across 3.6 million human CD4 T cells.
  • About 16% of activated genes significantly altered at least one surface protein. The data revealed five regulatory modules matching known T cell states—and showed that proteins can be co-regulated without being co-expressed in normal cells.
💡 Surface protein regulation in T cells is far more coordinated—and indirect—than transcription alone suggests.

Implications

CRISPR is no longer a single tool—it's a platform with nickases, activators, RNA-targeting variants, and in vivo delivery all maturing at once. The unresolved tension: as permanent in vivo edits move into broader clinical use, the field still lacks consensus on how to monitor for long-term off-target effects after a single irreversible dose.

Studies in this issue

Primary sources used for this newsletter.

  1. Gene editing for inherited angioedema: a major trial and remaining questions
    main storyMed (New York, N.Y.)2026-10-09PMID 42854678
  2. Changes in the Lid Part of Cas12a Enzyme Affect Its Cutting to a Single DNA Strand
    key findingNucleic acids research2026-10-05PMID 42831426
  3. A gene-editing method for human liver cells allows testing and confirming factors that affect hepatitis B virus
    key findingbioRxiv : the preprint server for biology2026-10-08PMID 42845553
  4. Genome-wide activation map of surface protein levels in human helper T cells
    key findingbioRxiv : the preprint server for biology2026-10-08PMID 42845358
  5. Genome-wide CRISPR screening found a non-neuron receptor called hemojuvelin for botulinum toxins A and C
    key findingCell reports2026-10-06PMID 42837260
  6. Glutathione's unexpected role in preventing cell damage by ferroptosis through FSP1
    key findingCell2026-10-06PMID 42838049
  7. Genome-edited sheep created by delivering prime editing proteins into fertilized eggs using electric pulses
    key findingFrontiers in genome editing2026-10-07PMID 42840083

Continue reading

All CRISPR Gene Editing issues